Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Jeffrey S BergerFrançois LalibertéAkshay KharatDominique LejeuneKenneth Todd MooreYoung JungPatrick LefebvreVeronica AshtonPublished in: Current medical research and opinion (2021)
These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- insulin resistance
- direct oral anticoagulants
- catheter ablation
- metabolic syndrome
- left atrial
- weight loss
- left atrial appendage
- venous thromboembolism
- type diabetes
- high fat diet induced
- weight gain
- heart failure
- percutaneous coronary intervention
- pulmonary embolism
- physical activity
- adipose tissue
- body mass index
- acute coronary syndrome
- mitral valve
- left ventricular
- smoking cessation
- replacement therapy
- coronary artery disease